|
Saturday, June 1, 2024, Chicago, Illinois, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time)
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Prostate CancerA CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, Illinois Phone: (312) 922-4400 Program Schedule — Central Time 6:30 PM – 7:00 PM — Registration and Dinner 7:00 PM – 9:00 PM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute University of Utah (NCI-CCC) Salt Lake City, Utah Emmanuel S Antonarakis, MD Clark Endowed Professor of Medicine Division of Hematology, Oncology and Transplantation University of Minnesota Minneapolis, Minnesota Andrew J Armstrong, MD, ScM Professor of Medicine, Surgery, Pharmacology and Cancer Biology Director of Research Duke Cancer Institute Center for Prostate and Urologic Cancers Divisions of Medical Oncology and Urology Duke University Durham, North Carolina Tanya B Dorff, MD Professor of Medicine Vice Chair for Clinical Affairs Department of Medical Oncology and Therapeutics Research Section Chief, Genitourinary Cancer Program City of Hope National Medical Center Los Angeles, California Matthew R Smith, MD, PhD Claire and John Bertucci Endowed Chair in Genitourinary Cancers Professor of Medicine Harvard Medical School Director, Genitourinary Malignancies Program Massachusetts General Hospital Cancer Center Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner 7:00 PM – 9:00 PM — Educational Meeting Discussion Topics
Target Audience
CME Credit Form Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Antonarakis — Advisory Committees: Aadi Bioscience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Curium, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus; Consulting Agreements: EcoR1 Capital LLC, Hookipa Pharma Inc, Lilly, Menarini Silicon Biosystems, Z-Alpha; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, MacroGenics Inc, Merck, Novartis, Orion Corporation, Seagen Inc; Patent Holder: QIAGEN. Dr Armstrong — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Exelixis Inc, GoodRx, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Epic Sciences, Exact Sciences Corporation, Exelixis Inc, Forma Therapeutics, GoodRx, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Dendreon Pharmaceuticals Inc, Forma Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Nonrelevant Financial Relationships: National Cancer Institute, National Institutes of Health, Prostate Cancer Foundation/Movember, US Department of Defense. Dr Smith — Advisory Committees: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Consulting Agreements: Ambrx, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Stock Options/Ownership — Public Company: Ambrx. Additional faculty to be announced. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck. Hilton Chicago
This activity is intended for medical and radiation oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the 2024 ASCO Annual Meeting. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. |